Corrigendum to "Candidate anti-tuberculosis medicines and regimens under clinical evaluation" [Clin Microbiol Infect 30(9) (2024) 1131-1138]

Affiliations

¹ Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, Munich, Germany; German Centre for Infection Research, Partner Site Munich, Munich, Germany; Fraunhofer Institute ITMP, Immunology, Infection and Pandemic Research, Munich, Germany; Unit Global Health, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany. Electronic address: hoelscher@lrz.uni-muenchen.de.
² GSK, Tres Cantos, Spain.
³ Otsuka Novel Products GmbH, Munich, Germany.
⁴ Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, Munich, Germany; German Centre for Infection Research, Partner Site Munich, Munich, Germany; Fraunhofer Institute ITMP, Immunology, Infection and Pandemic Research, Munich, Germany.
⁵ TB Alliance, New York, NY, United States.
⁶ Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany; German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany; Respiratory Medicine and International Health, University of Lübeck, Lübeck, Germany; Baylor College of Medicine and Texas Children Hospital, Global TB Program, Houston, TX, United States.
⁷ GSK, Brentford, United Kingdom; Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
⁸ Bill & Melinda Gates Medical Research Institute, Cambridge, MA, United States.

Free article

Published Erratum

Michael Hoelscher et al. Clin Microbiol Infect. 2025.

Free article

. 2025 Oct 9:S1198-743X(25)00497-5.

doi: 10.1016/j.cmi.2025.10.001. Online ahead of print.

¹ Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, Munich, Germany; German Centre for Infection Research, Partner Site Munich, Munich, Germany; Fraunhofer Institute ITMP, Immunology, Infection and Pandemic Research, Munich, Germany; Unit Global Health, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany. Electronic address: hoelscher@lrz.uni-muenchen.de.
² GSK, Tres Cantos, Spain.
³ Otsuka Novel Products GmbH, Munich, Germany.
⁴ Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, Munich, Germany; German Centre for Infection Research, Partner Site Munich, Munich, Germany; Fraunhofer Institute ITMP, Immunology, Infection and Pandemic Research, Munich, Germany.
⁵ TB Alliance, New York, NY, United States.
⁶ Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany; German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany; Respiratory Medicine and International Health, University of Lübeck, Lübeck, Germany; Baylor College of Medicine and Texas Children Hospital, Global TB Program, Houston, TX, United States.
⁷ GSK, Brentford, United Kingdom; Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
⁸ Bill & Melinda Gates Medical Research Institute, Cambridge, MA, United States.

No abstract available

Erratum for

Candidate anti-tuberculosis medicines and regimens under clinical evaluation.
Hoelscher M, Barros-Aguirre D, Dara M, Heinrich N, Sun E, Lange C, Tiberi S, Wells C. Hoelscher M, et al. Clin Microbiol Infect. 2024 Sep;30(9):1131-1138. doi: 10.1016/j.cmi.2024.06.016. Epub 2024 Jun 22. Clin Microbiol Infect. 2024. PMID: 38909687 Review.